KRAS and cancer: Co-occurring PI3K mutations did not influence OS (16.0 vs. 14.2 months, P = .62) or PFS (7.4 vs. 6.8 months, P = .91) for KRAS non-G12R mutated cancers (Fig 3C, 3F).